JP5362940B2 - 炎症性疾患治療用候補薬剤をスクリーニングするためのアッセイ - Google Patents
炎症性疾患治療用候補薬剤をスクリーニングするためのアッセイ Download PDFInfo
- Publication number
- JP5362940B2 JP5362940B2 JP2003547968A JP2003547968A JP5362940B2 JP 5362940 B2 JP5362940 B2 JP 5362940B2 JP 2003547968 A JP2003547968 A JP 2003547968A JP 2003547968 A JP2003547968 A JP 2003547968A JP 5362940 B2 JP5362940 B2 JP 5362940B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tetaiotaomicron
- pparγ
- inflammatory
- caco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 34
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- 238000003556 assay Methods 0.000 title abstract description 15
- 238000012216 screening Methods 0.000 title description 2
- 108010016731 PPAR gamma Proteins 0.000 claims abstract description 109
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 42
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 42
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 26
- 210000000172 cytosol Anatomy 0.000 claims abstract description 20
- 230000002103 transcriptional effect Effects 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 102000000536 PPAR gamma Human genes 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims description 52
- 108090000695 Cytokines Proteins 0.000 claims description 25
- 102000004127 Cytokines Human genes 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 206010061218 Inflammation Diseases 0.000 claims description 18
- 210000001842 enterocyte Anatomy 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 241000606125 Bacteroides Species 0.000 claims description 9
- 210000000987 immune system Anatomy 0.000 claims description 6
- 230000013632 homeostatic process Effects 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 210000002510 keratinocyte Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 189
- 230000000694 effects Effects 0.000 abstract description 35
- 238000000034 method Methods 0.000 abstract description 29
- 230000000968 intestinal effect Effects 0.000 abstract description 21
- 230000030147 nuclear export Effects 0.000 abstract description 14
- 102000040945 Transcription factor Human genes 0.000 abstract description 12
- 108091023040 Transcription factor Proteins 0.000 abstract description 12
- 230000016396 cytokine production Effects 0.000 abstract description 9
- 230000006195 histone acetylation Effects 0.000 abstract description 7
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 abstract description 4
- 230000012223 nuclear import Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 109
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 107
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 60
- 108090000623 proteins and genes Proteins 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 32
- 208000015181 infectious disease Diseases 0.000 description 31
- 102000003896 Myeloperoxidases Human genes 0.000 description 30
- 108090000235 Myeloperoxidases Proteins 0.000 description 30
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 27
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 27
- 210000004185 liver Anatomy 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108020004999 messenger RNA Proteins 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 24
- 102000004890 Interleukin-8 Human genes 0.000 description 22
- 108090001007 Interleukin-8 Proteins 0.000 description 22
- 238000011534 incubation Methods 0.000 description 22
- 101710124574 Synaptotagmin-1 Proteins 0.000 description 21
- 102100023132 Transcription factor Jun Human genes 0.000 description 21
- 102100035100 Transcription factor p65 Human genes 0.000 description 21
- 230000001580 bacterial effect Effects 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- 241000607142 Salmonella Species 0.000 description 20
- 210000000936 intestine Anatomy 0.000 description 20
- 241000194033 Enterococcus Species 0.000 description 19
- 210000001165 lymph node Anatomy 0.000 description 19
- 230000001404 mediated effect Effects 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 16
- 230000028709 inflammatory response Effects 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 244000052616 bacterial pathogen Species 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 210000000813 small intestine Anatomy 0.000 description 15
- 101150112014 Gapdh gene Proteins 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 13
- 230000009471 action Effects 0.000 description 13
- 238000009826 distribution Methods 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 210000002027 skeletal muscle Anatomy 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 230000001086 cytosolic effect Effects 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 241000588747 Klebsiella pneumoniae Species 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 210000002919 epithelial cell Anatomy 0.000 description 11
- 210000003736 gastrointestinal content Anatomy 0.000 description 11
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 11
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 10
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 10
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 10
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000005937 nuclear translocation Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 102000023984 PPAR alpha Human genes 0.000 description 9
- 206010039438 Salmonella Infections Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 210000003608 fece Anatomy 0.000 description 9
- 210000003405 ileum Anatomy 0.000 description 9
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 9
- 206010039447 salmonellosis Diseases 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000016951 Chemokine CXCL2 Human genes 0.000 description 8
- 108010014414 Chemokine CXCL2 Proteins 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 8
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 8
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 108010082025 cyan fluorescent protein Proteins 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 102100027584 Protein c-Fos Human genes 0.000 description 6
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002975 chemoattractant Substances 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004347 intestinal mucosa Anatomy 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- YACHGFWEQXFSBS-UHFFFAOYSA-N Leptomycin B Natural products OC(=O)C=C(C)CC(C)C(O)C(C)C(=O)C(C)C=C(C)C=CCC(C)C=C(CC)C=CC1OC(=O)C=CC1C YACHGFWEQXFSBS-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- YACHGFWEQXFSBS-XYERBDPFSA-N leptomycin B Chemical compound OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)/C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-XYERBDPFSA-N 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 239000003068 molecular probe Substances 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000007115 recruitment Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 description 4
- 108010031154 Transcription Factor RelA Proteins 0.000 description 4
- 102000005747 Transcription Factor RelA Human genes 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 230000006196 deacetylation Effects 0.000 description 4
- 238000003381 deacetylation reaction Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000008057 potassium phosphate buffer Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 4
- 230000034512 ubiquitination Effects 0.000 description 4
- 238000010798 ubiquitination Methods 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010014889 Enterococcal infections Diseases 0.000 description 3
- 102100029095 Exportin-1 Human genes 0.000 description 3
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 3
- 101000770943 Homo sapiens Exportin-1 Proteins 0.000 description 3
- 108010028275 Leukocyte Elastase Proteins 0.000 description 3
- 102000016799 Leukocyte elastase Human genes 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
- 229960002297 fenofibrate Drugs 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 210000000224 granular leucocyte Anatomy 0.000 description 3
- 108010074724 histone deacetylase 3 Proteins 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- 230000004207 intestinal integrity Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004942 nuclear accumulation Effects 0.000 description 3
- 244000039328 opportunistic pathogen Species 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000003614 peroxisome proliferator Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009919 sequestration Effects 0.000 description 3
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001099460 Homo sapiens Myeloperoxidase Proteins 0.000 description 2
- 102000008379 I-kappa B Proteins Human genes 0.000 description 2
- 108010021699 I-kappa B Proteins Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 2
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 108010039259 RNA Splicing Factors Proteins 0.000 description 2
- 102000015097 RNA Splicing Factors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008952 bacterial invasion Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 2
- 229950009226 ciglitazone Drugs 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 102000051251 human MPO Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 238000010820 immunofluorescence microscopy Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000037257 muscle growth Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- IFAOJWCXOQHSQT-LXIYXOSZSA-N 4-[[(2s)-1-[[(2s)-1-[[(2s)-3-methyl-1-(4-nitroanilino)-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 IFAOJWCXOQHSQT-LXIYXOSZSA-N 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 101100434480 Arabidopsis thaliana AFB2 gene Proteins 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 1
- 108050003758 Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 101150096607 Fosl2 gene Proteins 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 1
- 101000714470 Homo sapiens Synaptotagmin-1 Proteins 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 101150026829 JUNB gene Proteins 0.000 description 1
- 101150021395 JUND gene Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091008767 PPARγ2 Proteins 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 1
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 1
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010070346 Salmine Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 101710200257 Transcription factor atf-2 Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000004458 antinutrient Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108700025906 fos Genes Proteins 0.000 description 1
- 101150064107 fosB gene Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108700025907 jun Genes Proteins 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 108010016743 leucine receptor Proteins 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000004647 pro-inflammatory pathway Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0127916.5A GB0127916D0 (en) | 2001-11-21 | 2001-11-21 | Method |
| GB0127916.5 | 2001-11-21 | ||
| PCT/GB2002/005255 WO2003046580A1 (en) | 2001-11-21 | 2002-11-20 | Assay for screening candidate drugs for the treatment of inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012196103A Division JP2013046615A (ja) | 2001-11-21 | 2012-09-06 | 炎症性疾患治療用候補薬剤をスクリーニングするためのアッセイ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510733A JP2005510733A (ja) | 2005-04-21 |
| JP5362940B2 true JP5362940B2 (ja) | 2013-12-11 |
Family
ID=9926193
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547968A Expired - Fee Related JP5362940B2 (ja) | 2001-11-21 | 2002-11-20 | 炎症性疾患治療用候補薬剤をスクリーニングするためのアッセイ |
| JP2012196103A Pending JP2013046615A (ja) | 2001-11-21 | 2012-09-06 | 炎症性疾患治療用候補薬剤をスクリーニングするためのアッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012196103A Pending JP2013046615A (ja) | 2001-11-21 | 2012-09-06 | 炎症性疾患治療用候補薬剤をスクリーニングするためのアッセイ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7998474B2 (enExample) |
| EP (1) | EP1448995B9 (enExample) |
| JP (2) | JP5362940B2 (enExample) |
| AT (1) | ATE496302T1 (enExample) |
| AU (1) | AU2002343063B2 (enExample) |
| CA (1) | CA2468082C (enExample) |
| DE (1) | DE60239009D1 (enExample) |
| DK (1) | DK1448995T3 (enExample) |
| ES (1) | ES2362494T3 (enExample) |
| GB (1) | GB0127916D0 (enExample) |
| WO (1) | WO2003046580A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050390A1 (it) * | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| ES2473625T3 (es) * | 2007-10-26 | 2014-07-07 | Brenda E. Moore | Composición probi�tica y métodos para inducir y mantener la pérdida de peso |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| EA020856B1 (ru) | 2009-02-16 | 2015-02-27 | Джулиани Интернэшнл Лимитед | Способы лечения патологических состояний, связанных с волосами |
| US20140128276A1 (en) * | 2011-01-13 | 2014-05-08 | Oklahoma Medical Research Foundation | Cytokine profiles as methods for diagnosis and prognosis of irritable bowel syndrome |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| US20130022575A1 (en) * | 2011-07-19 | 2013-01-24 | Microbial Rx | Systems and methods of replacing intestinal flora |
| GB201117313D0 (en) * | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| DK2750682T3 (en) | 2011-10-11 | 2016-08-22 | Achim Biotherapeutics Ab | A composition comprising anaerobically cultured human intestinal flora |
| JP6301844B2 (ja) | 2012-02-09 | 2018-03-28 | ノグラ ファーマ リミテッド | 線維症の処置方法 |
| EP2830599B1 (en) | 2012-03-29 | 2018-08-15 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| EP2844242A1 (en) | 2012-04-18 | 2015-03-11 | Nogra Pharma Limited | Methods of treating lactose intolerance |
| WO2013188529A1 (en) | 2012-06-15 | 2013-12-19 | Temple University Of The Commonwealth System Of Higher Education | Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium |
| US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CN104546935A (zh) * | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| PE20171138A1 (es) | 2014-12-23 | 2017-08-09 | 4D Pharma Res Ltd | Modulacion inmunitaria |
| DK3193901T3 (en) | 2014-12-23 | 2018-05-28 | 4D Pharma Res Ltd | PIRIN POLYPEPTIDE AND IMMUNMODULATION |
| AU2018205072B2 (en) * | 2014-12-23 | 2020-05-21 | Cj Bioscience, Inc. | Immune modulation |
| FR3035329A1 (fr) * | 2015-04-23 | 2016-10-28 | Agronomique Inst Nat Rech | La prevention ou le traitement d'une infection par bacteroides thetaiotaomicron |
| EP3662917A1 (en) | 2015-06-15 | 2020-06-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| PE20180243A1 (es) | 2015-06-15 | 2018-01-31 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| LT3360559T (lt) | 2015-06-15 | 2019-12-27 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterijų kamienus |
| US20180088110A1 (en) * | 2015-08-17 | 2018-03-29 | Sekisui Medical Co., Ltd. | Immunological detection method and test strip used therefor |
| MA41013A (fr) | 2015-11-20 | 2017-08-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MX373290B (es) | 2016-03-04 | 2020-06-18 | 4D Pharma Plc | Composiciones que comprenden cepas bacterianas. |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI621708B (zh) * | 2016-06-15 | 2018-04-21 | ４Ｄ製藥研究有限公司 | 免疫調節 |
| TWI782800B (zh) * | 2016-06-15 | 2022-11-01 | 英商4D製藥研究有限公司 | 包含菌株之組合物及其用途、製法及產品 |
| TWI750342B (zh) * | 2016-06-15 | 2021-12-21 | 英商4D製藥研究有限公司 | 包含菌株之組合物及其用途、製法及產品 |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| MA48940A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| JP2020523326A (ja) | 2017-06-14 | 2020-08-06 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| PL3638271T3 (pl) | 2017-06-14 | 2021-03-22 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| TWI767013B (zh) | 2017-06-14 | 2022-06-11 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
| MX2020007665A (es) | 2018-01-19 | 2020-09-14 | 4D Pharma Res Limited | Terapia de combinacion para tratar o prevenir el cancer. |
| JP2021516216A (ja) | 2018-01-19 | 2021-07-01 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | がんを処置または予防するための併用療法 |
| MX2020007681A (es) | 2018-01-19 | 2020-09-14 | 4D Pharma Res Limited | Terapia de combinacion para tratar o prevenir el cancer. |
| JP2021516662A (ja) | 2018-01-19 | 2021-07-08 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | がんを処置または予防するための併用療法 |
| WO2019180051A1 (en) | 2018-03-19 | 2019-09-26 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| LT3743086T (lt) | 2018-05-11 | 2022-06-10 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterinius kamienus |
| AU2019287370A1 (en) | 2018-06-14 | 2021-01-07 | 4D Pharma Research Ltd | Compositions comprising bacterial strains |
| JP2021527639A (ja) | 2018-06-19 | 2021-10-14 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 生物療法製品を含む剤形 |
| EP3922256A1 (en) | 2018-06-25 | 2021-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| CN112566648A (zh) | 2018-07-16 | 2021-03-26 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| TW202023590A (zh) | 2018-08-17 | 2020-07-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| US12144834B2 (en) | 2018-09-13 | 2024-11-19 | Xbiome Inc. | Methods and compositions for treating gastrointestinal and inflammatory disorders |
| WO2020058499A1 (en) | 2018-09-20 | 2020-03-26 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| JP2022504185A (ja) * | 2018-10-09 | 2022-01-13 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| JP2022504423A (ja) | 2018-10-19 | 2022-01-13 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| TW202034949A (zh) | 2018-11-02 | 2020-10-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| AU2019396657A1 (en) | 2018-12-12 | 2021-07-08 | 4D Pharma Research Limited | Compositions comprising Parabacteroides bacterial strains for treating cancer |
| EP3893906A1 (en) | 2018-12-12 | 2021-10-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| WO2020120714A1 (en) | 2018-12-12 | 2020-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EP3921299B1 (en) | 2019-02-08 | 2024-11-20 | Nogra Pharma Limited | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
| TW202108153A (zh) | 2019-05-10 | 2021-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| EP4066844A1 (en) | 2019-07-05 | 2022-10-05 | 4D Pharma Research Limited | Compositions comprising anaerostipes hadrus |
| WO2021098991A1 (en) | 2019-11-20 | 2021-05-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EP3839039A1 (en) | 2019-12-16 | 2021-06-23 | 4D Pharma Research Limited | Providing bacterial biomass with improved storage stability |
| EP3838281A1 (en) | 2019-12-20 | 2021-06-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW202140773A (zh) | 2020-01-27 | 2021-11-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| TW202220639A (zh) | 2020-08-06 | 2022-06-01 | 英商４Ｄ製藥有限公司 | 凍乾方法 |
| CA3200126A1 (en) | 2020-11-26 | 2022-06-02 | Christophe Rene Leonard CARITE | Process |
| JPWO2022191182A1 (enExample) * | 2021-03-08 | 2022-09-15 | ||
| AU2022391025A1 (en) * | 2021-11-19 | 2024-06-06 | The Brigham And Women's Hospital, Inc. | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68928665T2 (de) | 1988-08-02 | 1998-11-12 | Gastro Services Pty Ltd | Behandlung von gastro-intestinalen krankheiten |
| US5443826A (en) * | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| US5039703A (en) * | 1989-11-16 | 1991-08-13 | Breuer Richard I | Method for treating inflammatory bowel disorders |
| US5599795A (en) * | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| GB9616047D0 (en) | 1996-07-31 | 1996-09-11 | Glaxo Group Ltd | Medicament carrier with agglomerated large medicament particles and related method of manufacture thereof |
| WO1998043081A1 (en) | 1997-03-26 | 1998-10-01 | Ligand Pharmaceuticals Incorporated | Treatment of gastrointestinal disease with ppar modulators |
| US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| US5951977A (en) * | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
| WO2001016120A1 (en) | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20040062757A1 (en) * | 2001-06-05 | 2004-04-01 | Finegold Sydney M. | Method of testing gastrointestinal diseases associated with species of genus clostridium |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| CA2443935A1 (en) * | 2001-04-18 | 2002-10-31 | Merck & Co., Inc. | Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
-
2001
- 2001-11-21 GB GBGB0127916.5A patent/GB0127916D0/en not_active Ceased
-
2002
- 2002-10-31 US US10/285,224 patent/US7998474B2/en not_active Expired - Fee Related
- 2002-11-20 AT AT02779724T patent/ATE496302T1/de not_active IP Right Cessation
- 2002-11-20 JP JP2003547968A patent/JP5362940B2/ja not_active Expired - Fee Related
- 2002-11-20 EP EP02779724A patent/EP1448995B9/en not_active Expired - Lifetime
- 2002-11-20 ES ES02779724T patent/ES2362494T3/es not_active Expired - Lifetime
- 2002-11-20 CA CA2468082A patent/CA2468082C/en not_active Expired - Lifetime
- 2002-11-20 DE DE60239009T patent/DE60239009D1/de not_active Expired - Lifetime
- 2002-11-20 DK DK02779724.0T patent/DK1448995T3/da active
- 2002-11-20 AU AU2002343063A patent/AU2002343063B2/en not_active Expired
- 2002-11-20 WO PCT/GB2002/005255 patent/WO2003046580A1/en not_active Ceased
-
2012
- 2012-09-06 JP JP2012196103A patent/JP2013046615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE496302T1 (de) | 2011-02-15 |
| CA2468082A1 (en) | 2003-06-05 |
| EP1448995B9 (en) | 2011-10-12 |
| AU2002343063A1 (en) | 2003-06-10 |
| DK1448995T3 (da) | 2011-05-16 |
| WO2003046580A1 (en) | 2003-06-05 |
| EP1448995B1 (en) | 2011-01-19 |
| US20030133875A1 (en) | 2003-07-17 |
| EP1448995A1 (en) | 2004-08-25 |
| JP2005510733A (ja) | 2005-04-21 |
| GB0127916D0 (en) | 2002-01-16 |
| US7998474B2 (en) | 2011-08-16 |
| AU2002343063B2 (en) | 2008-06-05 |
| DE60239009D1 (de) | 2011-03-03 |
| ES2362494T3 (es) | 2012-10-05 |
| JP2013046615A (ja) | 2013-03-07 |
| CA2468082C (en) | 2012-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510733A (ja) | 炎症性疾患治療用候補薬剤をスクリーニングするためのアッセイ | |
| Battaglini et al. | Gut microbiota in acute ischemic stroke: from pathophysiology to therapeutic implications | |
| Huang et al. | Effects of the dietary probiotic, Enterococcus faecium NCIMB11181, on the intestinal barrier and system immune status in Escherichia coli O78-challenged broiler chickens | |
| Lazar et al. | Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer | |
| Tremblay et al. | Bile acid administration elicits an intestinal antimicrobial program and reduces the bacterial burden in two mouse models of enteric infection | |
| Song et al. | Effects of inulin supplementation on intestinal barrier function and immunity in specific pathogen-free chickens with Salmonella infection | |
| Lu et al. | Lactic acid bacteria isolated from Korean kimchi activate the vitamin D receptor–autophagy signaling pathways | |
| Li et al. | Risks associated with high-dose Lactobacillus rhamnosus in an Escherichia coli model of piglet diarrhoea: intestinal microbiota and immune imbalances | |
| Liu et al. | Oral administration of Lactobacillus fermentum I5007 favors intestinal development and alters the intestinal microbiota in formula-fed piglets | |
| Kim et al. | Bifidobacterium lactis inhibits NF-κB in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice | |
| Yang et al. | Influence of orally fed a select mixture of Bacillus probiotics on intestinal T-cell migration in weaned MUC4 resistant pigs following Escherichia coli challenge | |
| Sokolova et al. | Helicobacter pylori induces type 4 secretion system-dependent, but CagA-independent activation of IκBs and NF-κB/RelA at early time points | |
| CN105008924B9 (zh) | 用于治疗和/或预防腹泻的益生菌菌株 | |
| Wijdeveld et al. | The interaction between microbiome and host central nervous system: the gut-brain axis as a potential new therapeutic target in the treatment of obesity and cardiometabolic disease | |
| RS58641B1 (sr) | Bakterija za upotrebu kao probiotik za nutritivne i medicinske primene | |
| Gao et al. | Effects of Clostridium perfringens beta2 toxin on apoptosis, inflammation, and barrier function of intestinal porcine epithelial cells | |
| Teng et al. | An early fecal microbiota transfer improves the intestinal conditions on microflora and immunoglobulin and antimicrobial peptides in piglets | |
| KR20170066543A (ko) | 포만 유도 및 포만감 지속이 필요한 대상체에서 포만 유도 및 포만감 지속을 위한 약학 및 식품 조성물 | |
| EP1906838A2 (en) | Modulation of microbial pathogen-host cell interactions | |
| EP3490602A1 (en) | Systems and methods for altering microbiome to reduce disease risk and manifestations of disease | |
| Zhang et al. | Bacillus amyloliquefaciens BLCC1-0238 alone or in combination with mannan-oligosaccharides alleviates subclinical necrotic enteritis in broilers | |
| Song et al. | Effect of fecal microbiota transplantation on early intestinal immune function and histomorphology of immune organs in chicks | |
| Karaffová et al. | Limosilactobacillus reuteri B1/1 modulated the intestinal immune response in preventing Salmonella Enteritidis PT4 infection in a chicken ileal explant model | |
| US20240285733A1 (en) | Aldehyde dehydrogenase producing bacteria and methods of using same | |
| Al-Salami et al. | Probiotics applications in autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080924 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081224 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090223 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091027 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100127 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100224 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100303 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100329 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100713 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101013 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101020 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101115 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101213 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110809 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111109 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120306 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120606 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120906 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130806 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130905 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5362940 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |